Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in infants with ARPKD
NCT04786574Phase 3Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of tolvaptan in autosomal recessive polycystic kidney disease (ARPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Planned start Jul 2022; status: withdrawn.
02
Drugs
tolvaptan
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on NCT04786574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786574.